- Home
- ISRG vs AZN Comparison
ISRG vs AZN Comparison
Compare ISRG & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISRG | AZN |
|---|---|---|
| Founded | 1995 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0B | 316.4B |
| IPO Year | 1998 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ISRG | AZN |
|---|---|---|
| Price | $371.39 | $169.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 1 |
| Target Price | ★ $591.32 | N/A |
| AVG Volume (30 Days) | 2.7M | ★ 4.1M |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 4.57 | N/A |
| Revenue | ★ $10,064,700,000.00 | N/A |
| Revenue This Year | $16.64 | $10.34 |
| Revenue Next Year | $13.91 | $6.43 |
| P/E Ratio | $81.34 | ★ $31.91 |
| Revenue Growth | ★ 20.51 | N/A |
| 52 Week Low | $328.57 | $72.90 |
| 52 Week High | $603.88 | $212.71 |
Technical Indicators
Market Signals| Indicator | ISRG | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 53.08 |
| Support Level | $328.57 | $164.06 |
| Resistance Level | $446.92 | $175.04 |
| Average True Range (ATR) | 10.60 | 2.51 |
| MACD | -0.61 | 1.54 |
| Stochastic Oscillator | 19.34 | 96.89 |
Price Performance
Historical ComparisonAbout ISRG Intuitive Surgical Inc.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.